Fetal complications reported with maternal vitamin K antagonist use during pregnancy.*
| Anticoagulant regimen . | Spontaneous abortions . | Congenital anomalies . | Fetal wastage . |
|---|---|---|---|
| *Pregnant women with mechanical heart valves | |||
| Data are from Chan et al.8 | |||
| Vitamin K antagonists throughout with/without heparin near term | 196/792 (24.8%) | 35/549 (6.4%) | 266/792 (33.6%) |
| Heparin starting at/before 6 weeks and throughout 1st trimester, then vitamin K antagonists with/without heparin near term | 19/129 (14.7%) | 0/108 (0.0%) | 21/129 (16.3%) |
| No anticoagulation | 2/35 (5.7%) | 2/33 (6.1%) | 7/35 (20.0%) |
| Anticoagulant regimen . | Spontaneous abortions . | Congenital anomalies . | Fetal wastage . |
|---|---|---|---|
| *Pregnant women with mechanical heart valves | |||
| Data are from Chan et al.8 | |||
| Vitamin K antagonists throughout with/without heparin near term | 196/792 (24.8%) | 35/549 (6.4%) | 266/792 (33.6%) |
| Heparin starting at/before 6 weeks and throughout 1st trimester, then vitamin K antagonists with/without heparin near term | 19/129 (14.7%) | 0/108 (0.0%) | 21/129 (16.3%) |
| No anticoagulation | 2/35 (5.7%) | 2/33 (6.1%) | 7/35 (20.0%) |